Iris Melanoma Clinical Trial
Official title:
Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma
This phase II trial is studying how well sorafenib works when given together with carboplatin and paclitaxel in treating patients with stage IV melanoma of the eye. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may help carboplatin and paclitaxel work better by making tumor cells more sensitive to the drugs. Sorafenib may also stop the growth of melanoma by blocking some of the enzymes needed for tumor cell growth and by blocking blood flow to the tumor. Giving sorafenib together with carboplatin and paclitaxel may kill more tumor cells.
Status | Completed |
Enrollment | 25 |
Est. completion date | November 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Criteria: - Histologically proven uveal melanoma - Must have documented disease progression during or after =< 1 prior systemic treatment - Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan - No tumor involving major vessels - Zubrod performance status 0-1 - Absolute neutrophil count > 1,500/mm^3 - Platelet count > 100,000/mm^3 - Creatinine =< 2 times upper limit of normal (ULN) - Bilirubin =< 2 times ULN - SGOT or SGPT =< 2 times ULN (5 times ULN if hepatic metastasis present) - INR in range (usually between 2 and 3) - No active bleeding - No bleeding diathesis, active coagulopathy, or pathological condition that carries a high risk of bleeding - No condition (e.g., gastrointestinal tract disease) affecting ability to take oral medication or requiring IV alimentation - Not pregnant or nursing - Fertile patients must use effective contraception - No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or any other cancer for which the patient has been disease-free for 5 years - At least 28 days since prior systemic treatment for this disease comprising 1 of the following: single chemotherapy agent/regimen; single immunotherapy agent/regimen; single investigational treatment agent/regimen - At least 21 days since prior major surgery - No prior sorafenib or any other agents targeting raf kinase or vascular endothelial growth factor (VEGF) or VEGF receptor - No prior surgical procedures affecting absorption - No concurrent systemic corticosteroid therapy - Topical and/or inhaled steroids are allowed - No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, and phenobarbital), rifampin, or Hypericum perforatum (St. John's wort) - No prophylactic granulocyte/platelet colony-stimulating factors during the first course of treatment - Concurrent full-dose oral anticoagulants (e.g., warfarin) are allowed provided all of the following criteria are met: in-range INR ; stable dose of oral anticoagulant; no active bleeding or high risk of bleeding - Stage IV disease - No known varices - No uncontrolled hypertension with systolic blood pressure (BP) > 140 mm Hg or diastolic BP > 90 mm Hg - No significant traumatic injury within the past 21 days - No active, uncontrolled peptic ulcer disease |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southwest Oncology Group | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate (Complete and Partial Response) | Complete response corresponds to complete disappearance of all measurable and non-measurable lesions with no new lesions. Partial response corresponds to greater than or equal to 30? decrease of sum of longest diameter of all target measurable lesions with no new lesion and non unequivocal progression of non-measurable disease. | Every 6 weeks for the first 8 cycles of therapy, then every three cycles (9 weeks) until progression | No |
Secondary | One-year Overall Survival | Measured from date of registration to study until death due to any caused with observations last known to be alive censored at the date of last contact | Every 6-9 weeks until progression, after progression every six months for first two years and annually thereafter up to 3 for up to 3 years after registration or until death | No |
Secondary | 6-month Progression-free Survival | Measured from the date of registration to the first of progression or death due to any cause with patients last known to be alive and progression-free censored at the date of last contact | Every 6 weeks for the first 8 cycles of therapy, and then every 9 weeks until disease progression for up to 3 years after registration or until death | No |
Secondary | Toxicity | Number of patients with Grade 3-5 adverse events that are related to study drug by given type of adverse event | Weekly during the first cycle of therapy, then prior to each cycle (one cycle = 3 weeks) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Terminated |
NCT02336763 -
Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
|
N/A | |
Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT02068586 -
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
|
Phase 2 | |
Completed |
NCT01100528 -
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
|
Phase 2 | |
Completed |
NCT00085189 -
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01143402 -
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Completed |
NCT00450255 -
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00089063 -
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
|
Phase 2 | |
Completed |
NCT00243061 -
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT01989572 -
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
|
Phase 3 | |
Terminated |
NCT01730157 -
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
|
Phase 0 | |
Completed |
NCT01413191 -
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 |